A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
Part of paid clinical trials in New Haven, Connecticut.
- Sponsor
- Bristol-Myers Squibb
- Study ID
- NCT07293351
- Phase
- PHASE1/PHASE2
- Status
- Recruiting
Conditions
- Advanced Renal Cell Carcinoma (RCC)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Pumitamig — DRUGSpecified dose on specified days
- Ipilimumab — DRUGSpecified dose on specified days
- Cabozantinib — DRUGSpecified dose on specified days
Study Details
The purpose of this study is to evaluate the safety, tolerability, and efficacy of Pumitamig alone or in combination with Ipilimumab or Cabozantinib in participants with advanced Renal Cell Carcinoma (RCC)
Key Dates
- Start date
- Mar 26, 2026
- Status verified
- May 2026
- Primary completion
- Nov 28, 2029
- Completion
- Nov 26, 2031
Study Design
- Enrollment
- 254 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Part 1A: Arm A
- Experimental: Part 1A: Arm B
- Experimental: Part 1B: Arm G
- Experimental: Part 1B: Arm H
- Experimental: Part 2A: Arm C
- Experimental: Part 2A: Arm D
- Experimental: Part 2B: Arm I
- Experimental: Part 2B: Arm J
- Experimental: Part 2C: Arm M
Primary Outcome Measure
Number of participants with adverse events (AEs) [ Time Frame: Up to approximately 2 years from end of treatment ]
Central Contacts
- BMS Clinical Trials Contact Center www.BMSClinicalTrials.com855-907-3286
- First line of the email MUST contain NCT # and Site #.
Locations (13)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Local Institution - 0117 | New Haven | Connecticut | 06510 | Site 0117 |
| Sibley Memorial Hospital | Washington D.C. | District of Columbia | 20016 | Yasser Ged, Site 0134 410-570-9410 |
| Local Institution - 0126 | Orlando | Florida | 32803 | Site 0126 |
| Local Institution - 0124 | Iowa City | Iowa | 52242 | Site 0124 |
| Johns Hopkins Hospital | Baltimore | Maryland | 21287 | Yasser Ged, Site 0123 410-570-9410 |
| Washington University School of Medicine | St Louis | Missouri | 63110 | Melissa Reimers, Site 0094 314-362-5740 |
| Local Institution - 0096 | Hauppauge | New York | 11788 | Site 0096 |
| Local Institution - 0135 | Cincinnati | Ohio | 45219 | Site 0135 |
| Local Institution - 0127 | Cleveland | Ohio | 44195 | Site 0127 |
| MUSC Hollings Cancer Center | Charleston | South Carolina | 29425 | Thai Ho, Site 0165 843-792-9300 |
| Carolina Urologic Research Center, LLC | Myrtle Beach | South Carolina | 29572 | Neal Shore, Site 0114 843-449-1010 |
| Local Institution - 0158 | Salt Lake City | Utah | 84112 | - |
| Local Institution - 0095 | Seattle | Washington | 98109-1023 | Site 0095 |